 BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 GLOBE NEWSWIRE -- BriaCell Therapeutics Corp. Nasdaq: BCTX, BCTXW TSX-V:BCT BriaCell or the Company, a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale of an additional 882,352 shares at the public offering price of US4.24 per share pursuant to the underwriters over-allotment option granted in connection with the Companys recent public offering, resulting in additional gross proceeds of approximately US3.7 million. After giving effect to the full exercise of the over-allotment option, the total gross proceeds for the public offering increased to approximately US28.7 million. 